Oakworth Capital Inc. Buys 23 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Oakworth Capital Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,767 shares of the medical research company’s stock after purchasing an additional 23 shares during the period. Oakworth Capital Inc.’s holdings in Thermo Fisher Scientific were worth $1,469,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Coppell Advisory Solutions LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $33,000. Live Oak Investment Partners bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $36,000. Tyler Stone Wealth Management bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $37,000. Raleigh Capital Management Inc. lifted its position in Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares during the last quarter. Finally, Cedar Mountain Advisors LLC lifted its position in Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 46 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 5,547 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the sale, the chief executive officer now owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 over the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of a number of analyst reports. Royal Bank of Canada increased their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Evercore ISI increased their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $6.78 during trading hours on Wednesday, reaching $547.77. The stock had a trading volume of 878,883 shares, compared to its average volume of 1,529,955. The stock’s 50 day moving average is $571.67 and its 200 day moving average is $526.87. The firm has a market capitalization of $209.09 billion, a PE ratio of 35.44, a PEG ratio of 2.34 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.40 earnings per share. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.